213 related articles for article (PubMed ID: 20883729)
21. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
Zajac M; Gomez G; Benitez J; Martínez-Delgado B
BMC Med Genomics; 2010 Oct; 3():44. PubMed ID: 20920318
[TBL] [Abstract][Full Text] [Related]
22. Distinct regulation of insulin receptor substrate-1 and -2 by 90-kDa heat-shock protein in adrenal chromaffin cells.
Yoshikawa N; Nemoto T; Satoh S; Maruta T; Yanagita T; Chosa E; Wada A
Neurochem Int; 2010 Jan; 56(1):42-50. PubMed ID: 19737590
[TBL] [Abstract][Full Text] [Related]
23. Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway.
Kimura T; Uesugi M; Takase K; Miyamoto N; Sawada K
Toxicol Appl Pharmacol; 2017 Aug; 329():282-292. PubMed ID: 28624441
[TBL] [Abstract][Full Text] [Related]
24. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
26. Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer.
Ruckova E; Muller P; Nenutil R; Vojtesek B
Cell Mol Biol Lett; 2012 Sep; 17(3):446-58. PubMed ID: 22669480
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
28. Hsp90 Inhibition Reduces TLR5 Surface Expression and NF-
Na BH; Hoang TX; Kim JY
Biomed Res Int; 2018; 2018():4319369. PubMed ID: 29651431
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells.
Lee CH; Hong HM; Chang YY; Chang WW
Biochimie; 2012 Jun; 94(6):1382-9. PubMed ID: 22445681
[TBL] [Abstract][Full Text] [Related]
30. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
Madrigal-Matute J; López-Franco O; Blanco-Colio LM; Muñoz-García B; Ramos-Mozo P; Ortega L; Egido J; Martín-Ventura JL
Cardiovasc Res; 2010 May; 86(2):330-7. PubMed ID: 20154064
[TBL] [Abstract][Full Text] [Related]
31. Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells.
Kang SA; Cho HS; Yoon JB; Chung IK; Lee ST
Biochem J; 2012 Oct; 447(2):313-20. PubMed ID: 22849407
[TBL] [Abstract][Full Text] [Related]
32. The effects of Hsp90 expression alteration on spinal metastases of breast carcinoma.
Yan W; Xiao J; Liu T; Huang W; Yang X; Wu Z; Huang Q; Qian M
Tumour Biol; 2013 Jun; 34(3):1391-7. PubMed ID: 23456764
[TBL] [Abstract][Full Text] [Related]
33. [Effect of HSP90 function inhibited on the telomerase and P53 mutant in breast cancer cells].
Li X; Deng HY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 39(2):181-3. PubMed ID: 18630678
[TBL] [Abstract][Full Text] [Related]
34. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
[TBL] [Abstract][Full Text] [Related]
35. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
36. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
37. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
[TBL] [Abstract][Full Text] [Related]
38. The role of heat shock protein 90 in migration and proliferation of vascular smooth muscle cells in the development of atherosclerosis.
Kim J; Jang SW; Park E; Oh M; Park S; Ko J
J Mol Cell Cardiol; 2014 Jul; 72():157-67. PubMed ID: 24650873
[TBL] [Abstract][Full Text] [Related]
39. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM
J Exp Med; 2012 Feb; 209(2):275-89. PubMed ID: 22271573
[TBL] [Abstract][Full Text] [Related]
40. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
